Your browser version may not work well with NCBI's Web applications. More information here...
1: J Thorac Oncol. 2008 Jan;3(1):94-7.Click here to read Links

Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.

Dham A, Truskinovsky AM, Dudek AZ.

Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.

Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma. We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor. After 3 weeks of treatment, tumor size significantly decreased to allow for a safe surgical resection with clear margins. We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.

PMID: 18166847 [PubMed - indexed for MEDLINE]

Related Articles

Patient Drug Information
  • Sunitinib (Sutent®) Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach) in people with tumors that wer...
    » read more ...